Systemic epidermal nevus with involvement of the oral mucosa due to FGFR3mutation
© Bygum et al; licensee BioMed Central Ltd. 2011
Received: 9 January 2011
Accepted: 5 June 2011
Published: 5 June 2011
Epidermal nevi (EN) represent benign congenital skin lesions following the lines of Blaschko. They result from genetic mosaicism, and activating FGFR3 and PIK3CA mutations have been implicated.
We report a female patient with a systemic keratinocytic nevus also involving the oral mucosa. Molecular genetic analysis revealed a mosaicism of the FGFR3 hotspot mutation R248C in the EN lesions of the skin and of the oral mucosa. The detection of the R248C mutation in a proportion of blood leukocytes and a slight scoliosis suggest an EN syndrome.
Our results show that activating FGFR3 mutations can also affect the oral mucosa and that extracutaneous manifestations of EN syndrome can be subtle. We highlight the theoretical risk of the patient having an offspring with thanatophoric dysplasia as gonadal mosaicism for the R248C mutation cannot be excluded.
Epidermal nevi (EN) are benign hamartomas of the skin arising from the embryonic ectoderm. Depending on the involved components of the epidermis, EN are further divided into organoid and non-organoid (keratinocytic) types . They are usually present at birth or develop during the first years of life, and their incidence is estimated to be 1-3 per 1000 live births . Keratinocytic nevi typically follow the lines of Blaschko. Systemic keratinocytic nevi are characterized by an extensive involvement of large skin areas and may be associated with skeletal, cerebral or ocular abnormalities, resulting in various types of EN syndromes [1, 2]. EN represent genetic mosaicism of the skin and activating FGFR3 (Fibroblast Growth Factor Receptor 3) and PIK3CA point mutations have recently been identified in keratinocytic nevi [3–6].
We report a patient with systemic EN associated with a slight scoliosis, who displayed mosaicism of the R248C FGFR3 mutation in epidermis, oral mucosa and blood leukocytes.
After informed consent of the patient and her parents, a 4 mm punch biopsy was taken from the chest. On histological examination, the biopsy showed a slightly papillomatous surface with non-specific laminated hyperkeratosis and acanthosis, typical of EN.
The patient was diagnosed with a bilateral, systemic keratinocytic nevus of the non-epidermolytic subtype. Maceration in the intertriginous areas was troublesome, but repeated laser (carbondioxide and Nd:YAG) treatments were without great success, as the skin lesions either relapsed or formed disfiguring scars.
Results of genetic analysis
3 Adjacent normal skin
4 Cultured fibroblasts (EN tissue)
5 Cultured fibroblasts (normal skin)
6 Hair roots
7 Intraoral EN
8 Urothelial cells
Immunohistochemical staining of the EN tissue with FGFR3 antibody (Santa Cruz Biotechnology, Santa Cruz, USA) revealed expression of FGFR3 protein in the complete epidermal layer, but the staining intensity was comparable with a normal skin control.
The results indicate that the systemic keratinocytic nevus syndrome in the present patient is caused by mosaicism of the R248C FGFR3 mutation. This mosaicism has extended to the oral mucosa, and caused intraoral lesions. The genetic mosaicism can be limited to the epidermis, but may also extend to other tissues, resulting in EN syndromes [1, 2]. The proportion of EN patients with additional abnormalities of other organ systems is not known, and may vary depending on the different subtypes of EN. One comprehensive study identified an EN syndrome in 33% of 119 EN patients .
In keratinocytic nevi, activating point mutations in FGFR3 and PIK3CA genes have been identified in about 40% of patients [5, 6]. Interestingly, the mutational spectrum is restricted to hotspots, including R248C for FGFR3 and E545G for PIK3CA. The same mutations have been identified in sporadic malignant tumors, and confer oncogenic properties to cells in vitro [9, 10]. A non-mosaic constitutional R248C FGFR3 mutation causes thanatophoric dysplasia, a typically lethal skeletal dysplasia . Obviously, surviving patients with the R248C FGFR3 mutation must be mosaics .
FGFR3 and PIK3CA mutations have also been identified in seborrheic keratoses which are benign epidermal skin tumors arising in adult patients with an increasing age-related incidence [5, 13–15]. Although the identified FGFR3 and PIK3CA mutations are oncogenic [10, 16, 17] and can activate downstream signalling pathways [18, 19], neither EN nor seborrheic keratoses bear a significant risk of malignant transformation.
In the patient of this case report, the R248C FGFR3 hotspot mutation was identified in the EN tissue of the skin and buccal mucosa (ectoderm) as well as a substantial proportion of blood leukocytes (mesoderm). With the involvement of two embryologic tissues, one might conclude that the mutation had happened at a very early stage, in a cell whose descendant population included skin and hematogenous precursor cells. The early occurrence of the mutation might be the reason for the widespread skin involvement.
To the best of our knowledge, we could show for the first time that the mosaic FGFR3 mutation can be associated with intraoral EN lesions, an otherwise uncommon observation . The wildtype sequence of unaffected skin, hair roots and cultured fibroblasts in our patient confirms that the R248C mutation occurred in a mosaic form restricted to the epithelium and absent from the stromal component of skin. We propose that this case represents an EN syndrome, given the presence of the mutation in blood leukocytes indicating bone marrow involvement. Even her slight scoliosis may be part of the syndrome, although the finding could be coincidental and independent from the mosaicism. Hitherto the R248C FGFR3 mutation has been identified in two cases of an EN syndrome: - one with facial dysmorphism, and the other patient with cerebral involvement [21, 22]. A preliminary designation of "FGFR3 EN syndrome" has been proposed, while acknowledging that a genetic heterogeneity may underlie the clinical phenotype of this syndrome [1, 22]. For patients with extensive EN, a work-up for EN syndrome is indicated even without obvious extracutaneous features, as in our case.
Furthermore, it is important to be aware that these patients may have a predisposition towards malignancies of internal organs, especially low grade urothelial carcinomas [23–25]. As yet, there has been no report identifying FGFR3 mutations in a patient with EN associated with urothelial cancer or other malignancies . However, FGFR3 mutations are involved in the pathogenesis of bladder tumors, cervix carcinoma, and multiple myeloma [9, 27]. The risk for the present patient is difficult to assess, although the absence of the FGFR3 mutation in urothelial cells suggests that at least for bladder cancer, it may be low. The risk for malignant transformation of an EN lesion (e.g., basal cell carcinoma or squamous cell carcinoma) appears likewise to be low, although occasional incidences have been reported [28–30].
If the FGFR3 mosaicism involves the gonad, our patient is at risk of having offspring with thanatophoric dysplasia. There is precedent for this, in a female patient with extensive mosaicism of the R248C FGFR3 mutation, including widespread acanthosis nigricans of the skin and skeletal dysplasia .
We show that a mosaicism of the R248C FGFR3 mutation can cause a systemic EN with involvement of the oral mucosa. For patients with extensive EN, a work-up for "EN syndrome" is indicated, as extracutaneous manifestations of the EN syndrome can be subtle. As gonadal mosaicism for the R248C FGFR3 mutation cannot be entirely excluded, a risk of having offspring with thanatophoric dysplasia exists. Prenatal diagnosis for the R248C mutation will therefore be offered in future pregnancies of our patient.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Acknowledgements and Funding
We thank Eva Herschberger for excellent technical support. This work was supported partly by a grant to C.H. from the Deutsche Forschungsgemeinschaft (DFG HA 5531/1).
- Happle R: The group of epidermal nevus syndromes Part I. Well defined phenotypes. J Am Acad Dermatol. 2010, 63: 1-22. 10.1016/j.jaad.2010.01.017.View ArticlePubMedGoogle Scholar
- Sugarman JL: Epidermal nevus syndromes. Semin Cutan Med Surg. 2007, 26: 221-230. 10.1016/j.sder.2008.03.006.View ArticlePubMedGoogle Scholar
- Happle R: Mosaicism in human skin. Understanding the patterns and mechanisms. Arch Dermatol. 1993, 129: 1460-1470. 10.1001/archderm.129.11.1460.View ArticlePubMedGoogle Scholar
- Happle R, Rogers M: Epidermal nevi. Adv Dermatol. 2002, 18: 175-201.PubMedGoogle Scholar
- Hafner C, López-Knowles E, Luis NM, Toll A, Baselga E, Fernández-Casado A, Hernández S, Ribé A, Mentzel T, Stoehr R, et al: Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci USA. 2007, 104: 13450-13454. 10.1073/pnas.0705218104.View ArticlePubMedPubMed CentralGoogle Scholar
- Hafner C, van Oers JM, Vogt T, Landthaler M, Stoehr R, Blaszyk H, Hofstaedter F, Zwarthoff EC, Hartmann A: Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest. 2006, 116: 2201-2207. 10.1172/JCI28163.View ArticlePubMedPubMed CentralGoogle Scholar
- Hurst CD, Zuiverloon TC, Hafner C, Zwarthoff EC, Knowles MA: A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res Notes. 2009, 2: 66-10.1186/1756-0500-2-66.View ArticlePubMedPubMed CentralGoogle Scholar
- Rogers M, McCrossin I, Commens C: Epidermal nevi and the epidermal nevus syndrome. A review of 131 cases. J Am Acad Dermatol. 1989, 20: 476-488. 10.1016/S0190-9622(89)70061-X.View ArticlePubMedGoogle Scholar
- Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999, 23: 18-20.PubMedGoogle Scholar
- Gymnopoulos M, Elsliger MA, Vogt PK: Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA. 2007, 104: 5569-5574. 10.1073/pnas.0701005104.View ArticlePubMedPubMed CentralGoogle Scholar
- Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin DJ, Lachman RS, Wilcox WR, Rimoin DL, Cohn DH, Wasmuth JJ: Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet. 1995, 9: 321-328. 10.1038/ng0395-321.View ArticlePubMedGoogle Scholar
- Happle R: Lethal genes surviving by mosaicism: a possible explanation for sporadic birth defects involving the skin. J Am Acad Dermatol. 1987, 16: 899-906. 10.1016/S0190-9622(87)80249-9.View ArticlePubMedGoogle Scholar
- Hafner C, van Oers JM, Hartmann A, Landthaler M, Stoehr R, Blaszyk H, Hofstaedter F, Zwarthoff EC, Vogt T: High Frequency of FGFR3 Mutations in Adenoid Seborrheic Keratoses. J Invest Dermatol. 2006, 126: 2404-2407. 10.1038/sj.jid.5700422.View ArticlePubMedGoogle Scholar
- Logié A, Dunois-Lardé C, Rosty C, Levrel O, Blanche M, Ribeiro A, Gasc JM, Jorcano J, Werner S, Sastre-Garau X, et al: Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet. 2005, 14: 1153-1160. 10.1093/hmg/ddi127.View ArticlePubMedGoogle Scholar
- Hafner C, Vogt T: Seborrheic keratosis. J Dtsch Dermatol Ges. 2008, 6: 664-677. 10.1111/j.1610-0387.2008.06788.x.View ArticlePubMedGoogle Scholar
- Bernard-Pierrot I, Brams A, Dunois-Lardé C, Caillault A, Diez de Medina SG, Cappellen D, Graff G, Thiery JP, Chopin D, Ricol D, et al: Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis. 2006, 27: 740-747.View ArticlePubMedGoogle Scholar
- Bader AG, Kang S, Vogt PK: Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA. 2006, 103: 1475-1479. 10.1073/pnas.0510857103.View ArticlePubMedPubMed CentralGoogle Scholar
- Hafner C, Di Martino E, Pitt E, Stempfl T, Tomlinson D, Hartmann A, Landthaler M, Knowles M, Vogt T: FGFR3 mutation affects cell growth, apoptosis and attachment in keratinocytes. Exp Cell Res. 2010, 316: 2008-2016. 10.1016/j.yexcr.2010.04.021.View ArticlePubMedGoogle Scholar
- Hafner C, Toll A, Fernández-Casado A, Earl J, Marqués M, Acquadro F, Méndez-Pertuz M, Urioste M, Malats N, Burns JE, et al: Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. Proc Natl Acad Sci USA. 2010, 107: 20780-20785. 10.1073/pnas.1008365107.View ArticlePubMedPubMed CentralGoogle Scholar
- Haberland-Carrodeguas C, Allen CM, Lovas JG, Hicks J, Flaitz CM, Carlos R, Stal S: Review of linear epidermal nevus with oral mucosal involvement--series of five new cases. Oral Dis. 2008, 14: 131-137. 10.1111/j.1601-0825.2006.01355.x.View ArticlePubMedGoogle Scholar
- Collin B, Taylor IB, Wilkie AO, Moss C: Fibroblast growth factor receptor 3 (FGFR3) mutation in a verrucous epidermal naevus associated with mild facial dysmorphism. Br J Dermatol. 2007, 156: 1353-1356. 10.1111/j.1365-2133.2007.07869.x.View ArticlePubMedGoogle Scholar
- García-Vargas A, Hafner C, Pérez-Rodríguez AG, Rodriguez-Rojas LX, González-Esqueda P, Stoehr R, Hernández-Torres M, Happle R: An epidermal nevus syndrome with cerebral involvement caused by a mosaic FGFR3 mutation. Am J Med Genet A. 2008, 2275-2279. 146A
- Rongioletti F, Rebora A: Epidermal nevus with transitional cell carcinomas of the urinary tract. J Am Acad Dermatol. 1991, 25 (5 Pt 1): 856-858.View ArticlePubMedGoogle Scholar
- Rosenthal D, Fretzin DF: Epidermal nevus syndrome: report of association with transitional cell carcinoma of the bladder. Pediatr Dermatol. 1986, 3: 455-458. 10.1111/j.1525-1470.1986.tb00650.x.View ArticlePubMedGoogle Scholar
- García de Jalón A, Azúa-Romeo J, Trivez MA, Pascual D, Blas M, Rioja LA: Epidermal naevus syndrome (Solomon's syndrome) associated with bladder cancer in a 20-year-old female. Scand J Urol Nephrol. 2004, 38: 85-87. 10.1080/00365590310017316.View ArticlePubMedGoogle Scholar
- Hernández S, Toll A, Baselga E, Ribé A, Azua-Romeo J, Pujol RM, Real FX: Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors. J Invest Dermatol. 2007, 127: 1664-1666.View ArticlePubMedGoogle Scholar
- Chesi M, Nardini E, Brents LA, Schröck E, Ried T, Kuehl WM, Bergsagel PL: Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997, 16: 260-264. 10.1038/ng0797-260.View ArticlePubMedPubMed CentralGoogle Scholar
- Ichikawa T, Saiki M, Kaneko M, Saida T: Squamous cell carcinoma arising in a verrucous epidermal nevus. Dermatology. 1996, 193: 135-138. 10.1159/000246229.View ArticlePubMedGoogle Scholar
- Hafner C, Klein A, Landthaler M, Vogt T: Clonality of basal cell carcinoma arising in an epidermal nevus. New insights provided by molecular analysis. Dermatology. 2009, 218: 278-281. 10.1159/000189209.View ArticlePubMedGoogle Scholar
- Sugarman JL: Epidermal nevus syndromes. Semin Cutan Med Surg. 2004, 23: 145-157. 10.1016/j.sder.2004.01.008.View ArticlePubMedGoogle Scholar
- Hyland VJ, Robertson SP, Flanagan S, Savarirayan R, Roscioli T, Masel J, Hayes M, Glass IA: Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia. Am J Med Genet A. 2003, 120: 157-168.View ArticleGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/12/79/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.